Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Commentary|Articles|June 1, 2026
Experts Weigh In on Finerenone's Priority Review for CKD in Type 1 Diabetes
Fact checked by: Ron Panarotti
With no new kidney-protective therapies approved in T1D for over 3 decades, experts break down the clinical significance of finerenone's FDA priority review and what pharmacists need to know.
Advertisement
Advertisement
For more than 3 decades, patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) have had few to no new therapeutic options specifically designed to slow kidney disease progression. That could soon change. The FDA has accepted a supplemental new drug application (sNDA) and granted priority review to finerenone (Kerendia; Bayer) for the treatment of adults with T1D and CKD, a regulatory milestone that experts say could reshape how clinicians approach this historically undertreated population.1
Related to this article
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Advertisement
Advertisement